Immune system response to ragweed allergens

The immune system response to ragweed allergens is a complex biological process rather than a single molecular target. It is characterized by a Type I hypersensitivity reaction initiated when the immune system misidentifies proteins from ragweed pollen, such as the major allergen Amb a 1, as harmful threats. This process involves the production of allergen-specific Immunoglobulin E (IgE) antibodies, which bind to high-affinity receptors on mast cells and basophils. Upon subsequent exposure, the allergen cross-links these IgE molecules, triggering the release of inflammatory mediators like histamine, leukotrienes, and cytokines, leading to symptoms of allergic rhinitis and asthma. Therapeutic management focuses on modulating this response through allergen immunotherapy to promote T-cell tolerance and the production of protective IgG4 antibodies, or by using drugs that inhibit specific components of the cascade, such as anti-IgE antibodies or antihistamines.

Other names

Ragweed allergyAmbrosia artemisiifolia pollen sensitizationType I hypersensitivity to ragweedRagweed-induced allergic rhinitis

Therapeutic strategies include allergen immunotherapy (AIT) to induce immunological tolerance, monoclonal antibodies to neutralize IgE, and pharmacological antagonists to block inflammatory mediators like histamine and leukotrienes.